Sermorelin Research Overview (also known as GHRH 1-29)
A synthetic 29-amino acid analog of endogenous GHRH (Growth Hormone Releasing Hormone), representing the biologically active fragment that stimulates pituitary GH secretion. Studied for natural pulsatile GH support, recovery improvement, sleep quality, fat metabolism, and healthy aging applications.
What Is Sermorelin?
Sermorelin is a synthetic 29-amino-acid peptide corresponding to the N-terminal fragment of native Growth Hormone Releasing Hormone (GHRH). FDA-approved in 1997 for diagnosis and treatment of GH deficiency in children (later withdrawn from the US market for commercial reasons), it remains widely used in anti-aging and research medicine as a GH secretagogue that stimulates endogenous GH release rather than replacing it.
Mechanism and Advantages Over Exogenous GH
Sermorelin binds to GHRH receptors on pituitary somatotroph cells, activating adenylyl cyclase and increasing intracellular cAMP to drive GH synthesis and secretion. Unlike exogenous GH, which bypasses pituitary regulation, Sermorelin-stimulated GH release remains subject to normal hypothalamic feedback: somatostatin continues to modulate the response, preserving the natural pulsatile GH architecture and protecting against receptor desensitization and side effects of sustained supra-physiological GH exposure.
Research Applications
Sermorelin is studied for adult GH deficiency, anti-aging body composition optimization, sleep quality improvement (GH pulses occur predominantly during slow-wave sleep), and post-surgical/post-injury recovery. It is frequently combined with Ipamorelin for synergistic GH release — the GHRH + GHRP combination being the most studied pairing in GH secretagogue research.
Quick Reference
| Literature-Reported Dose Range | 200–500 mcg daily |
| Literature-Reported Frequency | Once at bedtime (align with natural GH pulse) |
| Literature-Reported Cycle Length | 3-6 months continuous use, then 1-3 month break to prevent desensitization |
| Literature-Reported Washout | 1-3 months off between cycles, or use 5 days on/2 days off schedule |
| Storage | Lyophilized: 2-8°C up to 3 years; Reconstituted: 2-8°C for 10-30 days |
| Sites Reported in Studies | SubQ: Lower abdomen (avoid navel), anterior thigh, posterior upper arm - rotate sites |
| Timing | Bedtime administration 2+ hours after last meal for optimal GH response |
Research Indications
Muscle Growth
Lean Body Mass Enhancement
1.26 kg lean mass increase documented in elderly men with improved muscle strength tests
IGF-1 Mediated Growth
Stimulates endogenous IGF-1 production leading to muscle protein synthesis and growth
Athletic Performance Support
Enhanced recovery and muscle development through physiological GH stimulation
Anti-Aging
Age-Related GH Decline Reversal
Restores GH/IGF-1 levels approaching those of younger men in 60-78 year old subjects
Body Composition Improvement
Decreased adiposity and enhanced muscle-to-fat ratios in clinical studies
Skin Thickness Enhancement
GH-mediated improvements in skin quality and thickness documented in aging studies
Hormonal
Endogenous GH Stimulation
Stimulates body's own GH production while preserving hypothalamic-pituitary axis integrity
Natural Pulsatile Patterns
Maintains physiological GH secretion patterns unlike direct HGH square-wave exposure
Preserved Feedback Regulation
Allows natural somatostatin negative feedback to maintain homeostasis
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Anti-aging/Longevity | 200–500 mcg daily | Once at bedtime | SubQ |
| Athletic Performance | 300-500 mcg daily | Once at bedtime | SubQ |
| Pediatric GH Deficiency | 30 mcg/kg daily | Once at bedtime | SubQ |
| Diagnostic Testing | 1 mcg/kg IV | Single dose | IV bolus |
| Body Composition | 200 mcg daily | 5 days weekly | SubQ |
| Combination Therapy | 200 mcg + GHRP | Once daily | SubQ co-injection |
Timing
Bedtime administration 2+ hours after last meal for optimal GH response. Typical onset: iGF-1 elevation: 1-2 weeks; Body composition: 4-8 weeks; Full benefits: 3-6 months.
Peptide Interactions
Both are GHRH-pathway signals. They are alternatives rather than a validated combined exposure; concurrent use can confound GH/IGF-1 interpretation and is not recommended outside a specifically justified, monitored protocol.
Excellent combination producing 3-5 fold increases in GH release. GHRH and GHRP work through different pathways with proven synergistic effects in clinical studies.
Both are GHRH analogs — combining them creates receptor competition with no additive GH benefit. Choose one GHRH analog per protocol. CJC-1295 is generally preferred for longer half-life; Sermorelin is often preferred for gentler, more physiological GH stimulation.
Combined GHRH+GHRP-2 produces 54-fold GH increases compared to 20-fold with GHRH alone. Well-documented synergistic mechanism.
Somatostatin analogs directly block GH release by activating inhibitory somatostatin receptors, completely negating sermorelin therapeutic effects.
Another somatostatin analog that inhibits GH release through direct receptor antagonism, making combination with sermorelin counterproductive.
High-dose glucocorticoids suppress pituitary GH release and reduce GHRH receptor sensitivity. Requires dose adjustments and IGF-1 monitoring.
GH antagonizes insulin action through IGF-1-mediated effects. Monitor blood glucose and consider insulin dose adjustments during sermorelin therapy.
Essential combination as untreated hypothyroidism prevents sermorelin response. 6.5% of patients develop hypothyroidism requiring hormone replacement.
Reported Research Timeline
01Week 1–2 (reported in cited studies): iGF-1 levels begin to rise, possible improved sleep quality and recovery
02Week 2–4 (reported in cited studies): enhanced body composition changes begin, increased energy and well-being
03Week 4–8 (reported in cited studies): visible muscle tone improvements, fat reduction, skin quality enhancement
04Week 8–12 (reported in cited studies): sustained body composition improvements, optimal IGF-1 elevation achieved
05Month 3–6 (reported in cited studies): maximum benefits including muscle growth, fat loss, and anti-aging effects
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Monitor thyroid function - 6.5% develop hypothyroidism requiring hormone replacement
Check IGF-1 levels monthly initially, then every 3-6 months long-term
Injection site reactions occur in 16.7% of patients but are generally mild
Not Recommended in active malignancy, pituitary tumors, and pregnancy
Seek Medical Attention If:
Signs of pituitary tumor growth (headaches, vision changes)
Severe injection site reactions or generalized allergic responses
Uncontrolled diabetes or significant glucose intolerance development
New onset or worsening of malignancy symptoms
Quality Indicators
Verified Marker
Clear reconstituted solution
Should be completely clear and colorless without particles, cloudiness, or precipitation
Verified Marker
Pharmaceutical grade purity
Greater than 98% peptide purity per USP standards with sterile, nonpyrogenic lyophilized powder
Verified Marker
Proper cold chain storage
Maintained at 2-8°C throughout transport with protection from light and temperature extremes
Verified Marker
FDA-registered manufacturing
Produced in FDA-registered facilities following current Good Manufacturing Practices with third-party verification
Quality Concern
Cloudy or discolored solution
Any cloudiness, particles, color changes, or precipitation indicates degradation or contamination
Quality Concern
Incorrect molecular weight
Should be exactly 3,358 daltons (free base) or 3,418 daltons (acetate salt) - verify with COA
Acceptable Range
Room temperature exposure
Brief room temperature exposure acceptable up to 72 hours but should be refrigerated promptly
Research Citations
- Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy
Thorner, M., Rochiccioli, P., Colle, M., et al., 1996, Journal of Clinical Endocrinology & Metabolism - Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men
Corpas, E., Harman, S.M., Piñeyro, M.A., Roberson, R., Blackman, M.R., 1992, Journal of Clinical Endocrinology & Metabolism - Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency
Prakash, A., Goa, K.L., 1999, BioDrugs - Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
Walker, R.F., 2006, Clinical Interventions in Aging - A potentially effective drug for patients with recurrent glioma: sermorelin
Chang, Y., Huang, R., Zhai, Y., et al., 2021, Annals of Translational Medicine - Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males
Sinha, D.K., Balasubramanian, A., Tatem, A.J., et al., 2020, Translational Andrology and Urology - Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men
Vittone, J., Blackman, M.R., Busby-Whitehead, J., et al., 1997, Metabolism - Growth hormone-releasing hormone therapy in growth hormone-deficient children: Geref International Study Group
Geref International Study Group, 1996, Journal of Pediatric Endocrinology & Metabolism - Growth hormone secretagogues: history, mechanism of action, and clinical development
Ishida, J., Saitoh, M., Ebner, N., et al., 2020, JCSM Rapid Communications - Sermorelin acetate discontinuation - manufacturing, not safety related
FDA Center for Drug Evaluation and Research, 2013, FDA Communication - Online large volume sample staking preconcentration and separation of enantiomeric GHRH analogs by capillary electrophoresis
Otin J, Tran NT, Benoit A, 2023, Electrophoresis - A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review
Coutinho LFD, DE Oliveira Neves LF, Camilo RP, 2026, J Sports Med Phys Fitness - Probing for peptidic drugs (2-10 kDa) in doping control blood samples
Thomas A, Thilmany S, Hofmann A, 2022, Anal Sci Adv - Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples
Thomas A, Walpurgis K, Thevis M, 2024, J Mass Spectrom - The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration
Dominikowski A, Rękoś Z, Olejarz M, 2026, Front Endocrinol (Lausanne)
Research Focus
Growth hormone release, Anti-aging, GH deficiency, Body composition, Sleep quality
Verified Vendors Carrying Sermorelin
Frequently Asked Questions
What should researchers watch for with Sermorelin?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Sermorelin?
Week 1–2 (reported in cited studies): iGF-1 levels begin to rise, possible improved sleep quality and recovery
How is Sermorelin typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →